Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
Want to see IN:JAGSNPHARM full AI Analyst Report?
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹301.80
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹14.05B
Enterprise Value₹14.08B
Total Cash (Recent Filing)₹1.59B
Total Debt (Recent Filing)₹88.36M
Price to Earnings (P/E)37.1
Beta0.93
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)9.20
Shares Outstanding67,139,150
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthExtremely low leverage provides durable financial flexibility: the company can fund working capital, absorb cyclical downturns, pursue opportunistic M&A or invest in field force without raising costly debt. This conservatism reduces bankruptcy risk and supports long-term execution.
Strong Cash GenerationOperating cash flow materially above reported earnings and free cash flow nearly equal to earnings indicates high earnings quality and internal funding capacity. Reliable cash conversion enables sustained reinvestment in sales, modest buybacks/dividends, and reduces external financing dependence.
Re-accelerated Revenue And Healthy MarginsA sharp re-acceleration in top-line together with high gross and operating margins points to strong product pricing, branded portfolio strength, and operating leverage. These durable margin characteristics support cash flow and return on capital if revenue momentum is maintained.
Bears Say
Earnings VolatilityYear-to-year swings in net income reduce predictability of earnings and complicate capital allocation. Volatility can stem from episodic costs, pricing or demand shifts and undermines sustained return profiles, making long-term forecasting and valuation less certain.
Choppy Cash Conversion HistoryWhile recent FCF is strong, historical swings signal working-capital or timing irregularities. Persistent variability in cash conversion can impair the firm's ability to fund consistent dividends, capex or strategic investments and raises execution risk over the medium term.
Declining EPS TrendA materially negative EPS growth rate indicates profitability under pressure despite revenue gains. If EPS contraction persists, it suggests margin squeeze, one-off items, or rising costs that could erode shareholder returns and weaken metrics used for long-term strategic decisions.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹301.80 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹14.05B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 71 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Apr 27, 2026. The company reported ₹1.25 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.25.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 1.24%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 67,139,150 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹1.25 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.256%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―